Merck KGaA (OTCMKTS:MKKGY) Stock Rating Lowered by Zacks Research

Merck KGaA (OTCMKTS:MKKGY) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

Several other equities analysts have also issued reports on the company. HSBC raised Merck KGaA to a “hold” rating in a report on Monday, July 6th. Jefferies Financial Group initiated coverage on Merck KGaA in a research report on Tuesday, May 26th. They issued a “hold” rating on the stock. Finally, UBS Group cut Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Six investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Merck KGaA has an average rating of “Hold”.

Merck KGaA Price Performance

Merck KGaA stock opened at $32.24 on Thursday. Merck KGaA has a 52 week low of $23.73 and a 52 week high of $34.19. The company’s 50 day moving average price is $32.23 and its two-hundred day moving average price is $29.36. The company has a quick ratio of 1.00, a current ratio of 1.51 and a debt-to-equity ratio of 0.36. The stock has a market cap of $20.83 billion, a P/E ratio of 16.62, a P/E/G ratio of 2.62 and a beta of 0.98.

About Merck KGaA

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.